SUMOylation inhibitors synergize with FXR agonists in combating liver fibrosis
FXR agonists have been investigated for the treatment of non-alcoholic steatohepatitis and liver fibrosis but the clinical efficacy is not optimal. Here the authors show that enhanced FXR SUMOylation in activated hepatic stellate cells reduces FXR signaling and that this can be rescued by SUMOylatio...
Enregistré dans:
Auteurs principaux: | Jiyu Zhou, Shuang Cui, Qingxian He, Yitong Guo, Xiaojie Pan, Pengfei Zhang, Ningning Huang, Chaoliang Ge, Guangji Wang, Frank J. Gonzalez, Hong Wang, Haiping Hao |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Nature Portfolio
2020
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/cb0ac40b9ecd4e1ebc0d9be07e906d1a |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Discovery, optimization, and evaluation of non-bile acid FXR/TGR5 dual agonists
par: Sachiho Miyata, et autres
Publié: (2021) -
Novel FXR agonist nelumal A suppresses colitis and inflammation-related colorectal carcinogenesis
par: Tsuneyuki Miyazaki, et autres
Publié: (2021) -
Regulation of transforming growth factor-β signalling by SUMOylation and its role in fibrosis
par: Xinyi Wang, et autres
Publié: (2021) -
An inhalable nanoparticulate STING agonist synergizes with radiotherapy to confer long-term control of lung metastases
par: Yang Liu, et autres
Publié: (2019) -
Bacteriophages Synergize with the Gut Microbial Community To Combat <italic toggle="yes">Salmonella</italic>
par: Yue O. O. Hu, et autres
Publié: (2018)